

Special Issue

Immune Checkpoint Inhibitors (ICIs) in Cancer Immunotherapy: Intriguing Game Changers with Future Perspectives

Message from the Guest Editor

This Special Issue aims to inform our understanding of immune checkpoint inhibitors in cancer immunotherapy. We are pleased to invite you to contribute original research articles and reviews pertinent to all aspects of immune checkpoint inhibitors in cancer immunotherapy. Research areas may include—though are not limited to—the following topics:

- Pursuit of new druggable immune checkpoints.
- Overcoming cancer resistance to immune checkpoint inhibitors.
- Leveraging nanotechnology and bioengineering for the development of novel immune checkpoint inhibitors.
- Combining distinct types of immune checkpoint inhibitors or immune checkpoint inhibitors with other cancer treatment approaches.
- Validating predictive and prognostic biomarkers related to immune checkpoint inhibitors.
- Utilizing the genomic and the immune profiling of the tumors to personalize immune checkpoint inhibitors.
- Harnessing the artificial intelligence (AI) and the analysis of large-scale protein data from tumor samples to personalize immune checkpoint inhibitors.
- Understanding, predicting, and mitigating the immune-related toxicity.

Guest Editor

Dr. Maria V. Deligiorgi

Laboratory of Pharmacology–Clinical Pharmacology Unit, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/153639

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).